
## Markus Alexander Zeitlinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3292564/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison of non-invasive Staphylococcus aureus sampling methods on lesional skin in patients with atopic dermatitis. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 245-252.	2.9	6
2	ldentification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Molecular Cancer, 2022, 21, 7.	19.2	10
3	Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. Clinical Pharmacokinetics, 2022, , 1.	3.5	5
4	Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Detection Tests Using Oral, Anterior Nasal, and Nasopharyngeal Swabs: a Diagnostic Accuracy Study. Microbiology Spectrum, 2022, 10, e0202921.	3.0	44
5	High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	3
6	Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	4
7	Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Expert Review of Clinical Pharmacology, 2021, 14, 777-791.	3.1	4
8	Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an <i>In Vivo</i> Microdialysis Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0067921.	3.2	3
9	Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	9
10	Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents. Clinical Pharmacokinetics, 2020, 59, 827-847.	3.5	6
11	Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 2681-2689.	3.0	3
12	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2169-2177.	6.4	30
13	Impact of erythrocytes on bacterial growth and antimicrobial activity of selected antibiotics. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 485-495.	2.9	7
14	The European Association for Clinical Pharmacology and Therapeutics—25Âyears' young and going strong. European Journal of Clinical Pharmacology, 2019, 75, 743-750.	1.9	11
15	A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1097-1106.	3.0	5
16	Comment on "Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients― Clinical Pharmacokinetics, 2019, 58, 981-982.	3.5	0
17	Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. AAPS Journal, 2019, 21, 61.	4.4	14
18	Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. Scientific Reports, 2019, 9, 6512.	3.3	6

#	Article	IF	CITATIONS
19	High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. European Journal of Pharmaceutical Sciences, 2019, 131, 218-229.	4.0	12
20	In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid. Infection, 2019, 47, 565-570.	4.7	7
21	Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate <sup>11</sup> C-Metoclopramide Assessed with PET Imaging in Humans. Journal of Nuclear Medicine, 2019, 60, 985-991.	5.0	38
22	A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood–Brain Barrier. Journal of Nuclear Medicine, 2019, 60, 486-491.	5.0	25
23	Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV. Journal of Pharmaceutical and Biomedical Analysis, 2019, 163, 34-38.	2.8	19
24	Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 599-606.	1.6	18
25	Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides. Clinical Pharmacokinetics, 2018, 57, 797-816.	3.5	17
26	Extended infusion—putting the benefit into context. Lancet Infectious Diseases, The, 2018, 18, 380-381.	9.1	1
27	Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1091-1098.	2.9	6
28	Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology and Therapeutics, 2018, 104, 139-147.	4.7	43
29	Compatibility of linezolid with commercial peritoneal dialysis solutions. American Journal of Health-System Pharmacy, 2018, 75, 1467-1477.	1.0	3
30	Effect of Rifampicin on the Distribution of [ <sup>11</sup> C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Molecular Pharmaceutics, 2018, 15, 4589-4598.	4.6	17
31	Target site pharmacokinetics of doxycycline for rosacea in healthy volunteers is independent of the food effect. British Journal of Clinical Pharmacology, 2018, 84, 2625-2633.	2.4	9
32	Lack of dermal penetration of topically applied gentamicin as pharmacokinetic evidence indicating insufficient efficacy. Journal of Antimicrobial Chemotherapy, 2018, 73, 2823-2829.	3.0	7
33	Comment on: Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass. Journal of Antimicrobial Chemotherapy, 2018, 73, 2587-2588.	3.0	2
34	Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?. Drugs, 2018, 78, 799-808.	10.9	15
35	Effect of Pâ€glycoprotein inhibition at the blood–brain barrier on brain distribution of ( <i>R</i> )â€{ <sup>11</sup> C]verapamil in elderly <i>vs.</i> young subjects. British Journal of Clinical Pharmacology, 2017, 83, 1991-1999.	2.4	28
36	A Prediction Method for P-glycoprotein–Mediated Drug–Drug Interactions at the Human Blood–Brain Barrier From Blood Concentration–Time Profiles, Validated With PET Data. Journal of Pharmaceutical Sciences, 2017, 106, 2780-2786.	3.3	4

#	Article	IF	CITATIONS
37	Human Bile Reduces Antimicrobial Activity of Selected Antibiotics against Enterococcus faecalis and Escherichia coli <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
38	Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs inÂHumans. Gastroenterology, 2017, 152, 980-982.e3.	1.3	57
39	Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens. European Journal of Clinical Pharmacology, 2017, 73, 1609-1613.	1.9	13
40	Intravenous Fluid Challenge Decreases Intracellular Volume: A Bioimpedance Spectroscopy-Based Crossover Study in Healthy Volunteers. Scientific Reports, 2017, 7, 9644.	3.3	8
41	Assessment of P-Glycoprotein Transport Activity at the Human Blood–Retina Barrier with ( <i>R</i> )â€ <sup>11</sup> C-Verapamil PET. Journal of Nuclear Medicine, 2017, 58, 678-681.	5.0	23
42	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically III Patients. Clinical Pharmacokinetics, 2017, 56, 617-633.	3.5	47
43	Compatibility of Meropenem with Different Commercial Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2017, 37, 51-55.	2.3	5
44	Colistin dampens fibrinolysis and endothelial activation during endotoxaemia. Thrombosis and Haemostasis, 2017, 117, 1714-1721.	3.4	11
45	The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death and Disease, 2017, 8, e3135-e3135.	6.3	34
46	Understanding the Activity of Antibiotics in Cerebrospinal Fluid in vitro. Pharmacology, 2016, 97, 233-244.	2.2	12
47	Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. Antimicrobial Agents and Chemotherapy, 2016, 60, 3617-3625.	3.2	34
48	An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 390-395.	1.4	4
49	Influence of Different Peritoneal Dialysis Fluids on theln VitroActivity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin againstEscherichia Coli. Peritoneal Dialysis International, 2016, 36, 662-668.	2.3	8
50	Whole-Body Distribution and Radiation Dosimetry of <sup>11</sup> C-Elacridar and <sup>11</sup> C-Tariquidar in Humans. Journal of Nuclear Medicine, 2016, 57, 1265-1268.	5.0	11
51	Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3179-3184.	3.0	12
52	Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmacology, 2016, 98, 93-98.	2.2	3
53	Platelet activation at the onset of human endotoxemia is undetectable <i>in vivo</i> . Platelets, 2016, 27, 479-483.	2.3	26
54	Cerebral and Peripheral Metabolism to Predict Successful Reperfusion After Cardiac Arrest in Rats: A Microdialysis Study. Neurocritical Care, 2016, 24, 283-293.	2.4	16

#	Article	IF	CITATIONS
55	An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy, 2016, 60, 2790-2797.	3.2	14
56	Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 2016, 55, 47-77.	3.5	11
57	Microdialysis Assessment of Cerebral Perfusion during Cardiac Arrest, Extracorporeal Life Support and Cardiopulmonary Resuscitation in Rats – A Pilot Trial. PLoS ONE, 2016, 11, e0155303.	2.5	13
58	Feasibility of microdialysis for determination of protein binding and target site pharmacokinetics of colistin in vivo. Journal of Clinical Pharmacology, 2015, 55, 431-437.	2.0	16
59	Approaching Complete Inhibition of P-Glycoprotein at the Human Blood–Brain Barrier: An ( <i>R</i> )-[ <sup>11</sup> C]Verapamil PET Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 743-746.	4.3	74
60	A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. Journal of Dermatological Treatment, 2015, 26, 367-372.	2.2	10
61	Assessing the influence of diurnal variations and selective Xa inhibition on whole blood aggregometry. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 531-536.	1.2	4
62	Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. European Journal of Cardio-thoracic Surgery, 2015, 48, 758-764.	1.4	13
63	Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. European Journal of Clinical Pharmacology, 2015, 71, 1359-1364.	1.9	12
64	Development of a Population Pharmacokinetic Model Characterizing the Tissue Distribution of Azithromycin in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 6675-6684.	3.2	29
65	Assessing Pharmacokinetics of Different Doses of Fosfomycin in Laboratory Rats Enables Adequate Exposure for Pharmacodynamic Models. Pharmacology, 2014, 93, 65-68.	2.2	7
66	Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically III and Immunocompromised Patients. Vaccine Journal, 2014, 21, 867-876.	3.1	11
67	Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection. Journal of Clinical Pharmacology, 2014, 54, 1058-1062.	2.0	13
68	In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 2014, 83, 1326-1331.	1.1	37
69	A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi Sensu Lato. Vaccine Journal, 2014, 21, 1490-1499.	3.1	36
70	Removal of fractured endodontic instruments using an Nd:YAG laser. Quintessence International, 2014, 45, 569-75.	0.4	3
71	Pilot Investigation on Long-Term Subcutaneous Microdialysis: Proof of Principle in Humans. AAPS Journal, 2013, 15, 95-103.	4.4	16
72	Reply. Annals of Thoracic Surgery, 2013, 96, 1528-1529.	1.3	0

5

#	Article	IF	CITATIONS
73	Neutralization of Antimicrobial Substances in New BacT/Alert FA and FN Plus Blood Culture Bottles. Journal of Clinical Microbiology, 2013, 51, 1534-1540.	3.9	41
74	Internal Mammary Artery Harvesting Influences Antibiotic Penetration Into Presternal Tissue. Annals of Thoracic Surgery, 2013, 95, 1323-1330.	1.3	35
75	Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infectious Diseases, The, 2013, 13, 680-689.	9.1	84
76	Interaction of <sup>11</sup> C-Tariquidar and <sup>11</sup> C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood–Brain Barrier. Journal of Nuclear Medicine, 2013, 54, 1181-1187.	5.0	45
77	Methods to Measure Target Site Penetration of Antibiotics in Critically III Patients. Current Clinical Pharmacology, 2013, 8, 46-58.	0.6	1
78	Methods to measure target site penetration of antibiotics in critically ill patients. Current Clinical Pharmacology, 2013, 8, 46-58.	0.6	5
79	Good Penetration of Moxifloxacin into Human Abscesses. Pharmacology, 2012, 90, 146-150.	2.2	4
80	Penetration of Doripenem into Skeletal Muscle and Subcutaneous Adipose Tissue in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2012, 56, 532-535.	3.2	16
81	Pharmacokinetics of Intraperitoneal and Intravenous Fosfomycin in Automated Peritoneal Dialysis Patients without Peritonitis. Antimicrobial Agents and Chemotherapy, 2012, 56, 3992-3995.	3.2	21
82	Absolute Oral Bioavailability and Metabolic Turnover of β-Sitosterol in Healthy Subjects. Drug Metabolism and Disposition, 2012, 40, 2026-2030.	3.3	31
83	A Randomised, Two-Period, Cross-Over, Open-Label Study to Evaluate the Pharmacokinetic Profiles of Single Doses of Two Different Flurbiprofen 8.75-mg Lozenges in Healthy Volunteers. Pharmacology, 2012, 89, 188-191.	2.2	5
84	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica, 2012, 97, 1431-1438.	3.5	96
85	Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming. Vaccine, 2012, 30, 6127-6135.	3.8	23
86	Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid. Research in Microbiology, 2012, 163, 157-160.	2.1	8
87	Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine, 2012, 30, 4543-4551.	3.8	15
88	Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury. International Journal of Antimicrobial Agents, 2012, 39, 343-345.	2.5	15
89	Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus. European Journal of Clinical Pharmacology, 2012, 68, 1419-1423.	1.9	0
90	Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 383-390.	0.6	25

#	Article	IF	CITATIONS
91	A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil. Clinical Pharmacokinetics, 2011, 50, 111-120.	3.5	31
92	Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. Research in Microbiology, 2011, 162, 249-252.	2.1	41
93	Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Blood–Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 510-515.	4.3	34
94	Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine, 2010, 29, 166-173.	3.8	26
95	Intra-Cystic Drug Concentration of Albendazole Sulphoxide in Patients with Echinococcus granulosus Cysts. American Journal of Tropical Medicine and Hygiene, 2009, 81, 712-713.	1.4	15
96	A Cell Culture (Vero)–Derived H5N1 Wholeâ€Virus Vaccine Induces Crossâ€Reactive Memory Responses. Journal of Infectious Diseases, 2009, 200, 1113-1118.	4.0	48
97	Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. Journal of Antimicrobial Chemotherapy, 2009, 64, 821-823.	3.0	19
98	A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with ( <i>R</i> )- <sup>11</sup> C-Verapamil and PET. Journal of Nuclear Medicine, 2009, 50, 1954-1961.	5.0	99
99	"latrogenicity cascade": Doing harm by treating harm?. Wiener Medizinische Wochenschrift, 2009, 159, 53-57.	1.1	0
100	Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. European Journal of Clinical Pharmacology, 2009, 65, 941-946.	1.9	65
101	Protein Binding of Antimicrobials: Methods for Quantification and for Investigation of its Impact on Bacterial Killing. AAPS Journal, 2009, 11, 1-12.	4.4	56
102	Ketolides – The Modern Relatives of Macrolides. Clinical Pharmacokinetics, 2009, 48, 23-38.	3.5	29
103	The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. Intensive Care Medicine, 2008, 34, 1827-1834.	8.2	36
104	A combined accelerator mass spectrometry/positron emission tomography microdose study to assess the plasma and brain tissue pharmacokinetics of 11C- and 14C-labelled verapamil in healthy volunteers. BMC Pharmacology, 2008, 8, .	0.4	2
105	Plasma protein binding of fluoroquinolones affects antimicrobial activity. Journal of Antimicrobial Chemotherapy, 2008, 61, 561-567.	3.0	44
106	Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro. Journal of Antimicrobial Chemotherapy, 2008, 62, 1057-1060.	3.0	13
107	Pharmacokinetics of Single- and Multiple-Dose Oral Clarithromycin in Soft Tissues Determined by Microdialysis. Antimicrobial Agents and Chemotherapy, 2007, 51, 3185-3189.	3.2	42
108	Immunomodulatory Effects of Fosfomycin in Experimental Human Endotoxemia. Antimicrobial Agents and Chemotherapy, 2007, 51, 1879-1881.	3.2	15

#	Article	IF	CITATIONS
109	Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. Journal of Antimicrobial Chemotherapy, 2006, 58, 367-371.	3.0	32
110	Development of a high-performance liquid chromatography method for the determination of caspofungin with amperometric detection and its application to in vitro microdialysis experiments. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 843, 142-146.	2.3	20
111	Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. Journal of Antimicrobial Chemotherapy, 2006, 59, 219-223.	3.0	19
112	Lung microdialysisâ $\in$ "A powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS Journal, 2005, 7, E600-E608.	4.4	50
113	Pharmacokinetics and Pharmacodynamics of Cefpirome in Subcutaneous Adipose Tissue of Septic Patients. Antimicrobial Agents and Chemotherapy, 2005, 49, 650-655.	3.2	57
114	Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses. Antimicrobial Agents and Chemotherapy, 2005, 49, 2367-2371.	3.2	78
115	Influence of the Washing Buffer Composition on the Sensitivity of an Enzymeâ€Linked Immunosorbent Assay Using Mycobacterial Clycolipids as Capture Antigens. Journal of Immunoassay and Immunochemistry, 2005, 26, 179-188.	1.1	8
116	Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. Journal of Nuclear Medicine, 2005, 46, 1835-41.	5.0	35
117	[ 18 F]Ciprofloxacin, a New Positron Emission Tomography Tracer for Noninvasive Assessment of the Tissue Distribution and Pharmacokinetics of Ciprofloxacin in Humans. Antimicrobial Agents and Chemotherapy, 2004, 48, 3850-3857.	3.2	54
118	Pharmacokinetics of Telithromycin in Plasma and Soft Tissues after Single-Dose Administration to Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2004, 48, 4650-4653.	3.2	25
119	Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. Journal of Antimicrobial Chemotherapy, 2004, 53, 848-852.	3.0	107
120	Clinical Applications of Levofloxacin for Severe Infections. Chemotherapy, 2004, 50, 16-21.	1.6	12
121	Tissue pharmacokinetics of levofloxacin in human soft tissue infections. British Journal of Clinical Pharmacology, 2004, 57, 563-568.	2.4	42
122	Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model. International Journal of Antimicrobial Agents, 2003, 22, 574-578.	2.5	14
123	Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nuclear Medicine and Biology, 2003, 30, 285-291.	0.6	123
124	Target site penetration of fosfomycin in critically ill patients. Journal of Antimicrobial Chemotherapy, 2003, 51, 1247-1252.	3.0	114
125	Circulating Tuberculostearic Acid in Tuberculosis Patients. Scandinavian Journal of Infectious Diseases, 2003, 35, 790-793.	1.5	11
126	Target Site Concentrations of Ciprofloxacin after Single Intravenous and Oral Doses. Antimicrobial Agents and Chemotherapy, 2002, 46, 3724-3730.	3.2	63